Healthcare ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Research and Development AI in Healthcare Market Trends GLP-1 Medications Obesity Treatments Innovation Obesity Treatment Antiviral Drugs Antibiotics

Court Rules Liquidia’s Yutrepia Infringes United Therapeutics Patent

A Delaware decision sets a near‑term remedies timetable that could narrow Yutrepia’s approved PH‑ILD use.

Novo Nordisk Sues Eli Lilly Over National Ads for Obesity Drugs

Hackers Claim More Than 1TB Stolen From Novo Nordisk

Sanofi Launches 'Concierge for Field' AI Sales Agent Built on Snowflake

Pfizer and Innovent Strike Up to $10.5 Billion Oncology Collaboration

AstraZeneca Revives UK Plans With £300 Million for Cambridge and Macclesfield

Investor Law Firms Rally uniQure Case as April 13 Lead-Plaintiff Deadline Nears

AstraZeneca Posts Strong 2025 Results, Sees Further Growth in 2026

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Vistagen Faces Federal Securities Class Action After Fasedienol Phase 3 Failure

GSK Chief Says U.S. Is Best Place to Invest as UK Softens Drug Pricing Rules

Eli Lilly Picks Huntsville for $6 Billion API Plant to Supply Next-Gen Drugs

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Eli Lilly Plans Multi-Billion Katwijk Plant as CEO Criticizes Europe on Drug Policy

UK Signals Openness to Higher NHS Drug Prices After Pharma Backlash

Teva’s Olanzapine LAI Shows No PDSS in Phase 3 SOLARIS Long-Term Data Presented at Psych Congress

AstraZeneca H1 Revenue Jumps 11% as It Pledges $50 Billion U.S. Expansion

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030